Method and composition for crystallizing G protein-coupled receptors
View Patent ↗Certain embodiments provide a method for crystallizing a GPCR. The method may employ a fusion protein comprising: a) a first portion of a G-protein coupled receptor (GPCR), where the first portion comprises the TM1, TM2, TM3, TM4 and TM5 regions of the GPCR; b) a stable, folded protein insertion; and c) a second portion of the GPCR, where the second portion comprises the TM6 and TM7 regions of the GPCR.
1. An isolated GPCR fusion protein comprising, from N-terminus to C-terminus:
i. a first portion of a G-protein coupled receptor (GPCR), wherein said first portion comprises TM1, TM2, TM3, TM4 and TM5 regions of said GPCR;
ii. a domain comprising the amino acid sequence of a lysozyme; and
iii. a second portion of said GPCR, wherein said second portion comprises TM6 and TM7 regions of said GPCR.
2. The isolated GPCR fusion protein of claim 1 , wherein said isolated GPCR fusion protein is present in an isolated membrane.
3. The isolated GPCR fusion protein of claim 1 , wherein said isolated GPCR fusion protein is present on the surface of a cell.
4. The isolated GPCR fusion protein of claim 1 , wherein said isolated GPCR fusion protein is epitope tagged.
5. The isolated GPCR fusion protein of claim 1 , wherein said isolated GPCR fusion protein is active.
6. The isolated GPCR fusion protein of claim 1 , wherein said domain comprises an amino acid sequence having at least 80% identity to the amino acid sequence of a wild-type lysozyme.
7. The isolated GPCR fusion protein of claim 1 , wherein said domain comprises an amino acid sequence having at least 95% identity to a wild-type lysozyme.
8. The isolated GPCR fusion protein of claim 1 , wherein said domain comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of T4 lysozyme.
9. The isolated GPCR fusion protein of claim 1 , wherein said first and second portions of said GPCR comprise the amino acid sequence of a naturally occurring GPCR.
10. The isolated GPCR fusion protein of claim 1 , wherein said first and second portions of said GPCR comprise the amino acid sequence of a non-naturally occurring GPCR.
11. The isolated GPCR fusion protein of claim 1 , wherein the amino acid sequence of said first and second portions of said GPCR are least 80% identical to amino acid sequences of a wild type GPCR.
12. The isolated GPCR fusion protein acid of claim 1 , wherein said a GPCR is selected from the group consisting of: a receptor for a biogenic amine, a dopamine receptor, a serotonin receptor, an adrenergic receptor, a β2-adrenergic receptor, a melanocortin receptor subtype 4, a ghrelin receptor, a metabotropic glutamate receptor and a chemokine receptor.
13. The isolated GPCR fusion protein of claim 1 , wherein said domain is in the range of from 100 to 200 amino acids in length.
14. A polypeptide comprising, from N-terminus to C-terminus:
a) a first portion of a G-protein coupled receptor (GPCR), wherein said first portion comprises the amino acid sequence that is N-terminal to the IC3 loop of said GPCR;
b) a domain comprising the amino acid sequence of a lysozyme;
c) a second portion of said GPCR, wherein said second portion comprises the amino acid sequence that is C-terminal to the IC3 loop of said GPCR.
15. The polypeptide of claim 14 , wherein said domain spaces the C-terminal end of the first portion of said GPCR and the N-terminal end of the second region of said GPCR so that the closest alpha carbon atoms at said C-terminal end and said N-terminal end are spaced by a distance of in the range of 6 Å to 16 Å.
16. An isolated G-protein coupled receptor (GPCR) comprising an IC3 loop containing a substitution that comprises the amino acid sequence of a lysozyme.